Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study

References

• Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–1917. doi:10.1016/S0140-6736(03)14964-1
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739. doi:10.1016/S0140-6736(02)08649-X
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171. doi:10.1053/jhep.2002.33156
   PubMed Web of Science ®Google Scholar
• Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterol. 2006;131(2):461–469. doi:10.1053/j.gastro.2006.05.021
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682–720. doi:10.1159/000509424
   PubMed Web of Science ®Google Scholar
• Pleguezuelo M, Marelli L, Misseri M, et al. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2008;8(10):1623–1641. doi:10.1586/14737140.8.10.1623
   PubMed Web of Science ®Google Scholar
• Saito R, Amemiya H, Hosomura N, et al. Intended preoperative trans-arterial embolization for large hepatocellular carcinoma: a retrospective cohort study. World J Surg Oncol. 2022;20(1):90. doi:10.1186/s12957-022-02563-9
   PubMed Web of Science ®Google Scholar
• Yasuda S, Ito H, Yoshikawa M, et al. Radiotherapy for large hepatocellular carcinoma combined with transcatheter arterial embolization and percutaneous ethanol injection therapy. Int J Oncol. 1999;15(3):467–473.
   PubMed Web of Science ®Google Scholar
• Wang K, Guo WX, Chen MS, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity mathching score analysis. Medicine. 2016;95(11):e3015. doi:10.1097/MD.0000000000003015
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60–69. doi:10.1016/j.jhep.2018.02.008
   PubMed Web of Science ®Google Scholar
• Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, Phase III trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468–480. doi:10.1200/JCO.21.01963
   PubMed Web of Science ®Google Scholar
• He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–960. doi:10.1001/jamaoncol.2019.0250
   PubMed Web of Science ®Google Scholar
• Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized Phase II trial. Ann Oncol. 2016;27(11):2090–2096. doi:10.1093/annonc/mdw323
   PubMed Web of Science ®Google Scholar
• Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World J Gastroenterol. 2016;22(32):7289–7300. doi:10.3748/wjg.v22.i32.7289
   PubMed Web of Science ®Google Scholar
• Deng ZJ, Li L, Teng YX, et al. Treatments of hepatocellular carcinoma with portal vein tumor thrombus: current status and controversy. J Clin Transl Hepatol. 2022;10(1):147–158. doi:10.14218/JCTH.2021.00179
   PubMed Web of Science ®Google Scholar
• Sidaway P. FOLFOX-HAIC active in large HCC. Nat Rev Clin Oncol. 2022;19(1):5. doi:10.1038/s41571-021-00577-y
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Breder VV, Vogel A, Merle P, et al. Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. J Clin Oncol. 2021;39(15_suppl):4073. doi:10.1200/JCO.2021.39.15_suppl.4073
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab M, Sultan AM, Fathy OM, et al. Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma. Hepatogastroenty. 2013;60(128):1847–1853.
   PubMedGoogle Scholar
• Kudo M, Izumi N, Sakamoto M, et al. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer. 2016;5(3):190–197. doi:10.1159/000367775
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Murray SM, Forner A, et al. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. 2021;9(9):e003311. doi:10.1136/jitc-2021-003311
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International. 2021;100(1):215–224. doi:10.1016/j.kint.2021.03.033
   PubMed Web of Science ®Google Scholar
• Mei J, Tang YH, Wei W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular Carcinoma. Front Oncol. 2021; 11(618206):doi:10.3389/fonc.2021.618206
   Google Scholar
• Liu BJ, Gao S, Zhu X, et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy. 2021;13(17):1395–1405. doi:10.2217/imt-2021-0192
   PubMed Web of Science ®Google Scholar
• Chen S, Xu B, Wu Z, et al. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. BMC Cancer. 2021;21(1):1126. doi:10.1186/s12885-021-08858-6
   PubMed Web of Science ®Google Scholar
• Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117–127. doi:10.1200/JCO.22.00392
   PubMed Web of Science ®Google Scholar
• Li B, Qiiu J, Zheng Y, et al. Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma. Ann Surg Open. 2021;2(2):e057. doi:10.1097/AS9.0000000000000057
   PubMedGoogle Scholar
• Wu Z, Gao J, Zhuang W, Yang J, Guo W. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk. J Cancer Res Ther. 2022;18(2):345–351. doi:10.4103/jcrt.jcrt_1078_21
   PubMed Web of Science ®Google Scholar
• Ben Khaled N, Seidensticker M, Ricke J, et al. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncol. 2022;18(12):1423–1435. doi:10.2217/fon-2021-1261
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97–111. doi:10.1038/nri.2016.107
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi:10.1038/nature14011
   PubMed Web of Science ®Google Scholar
• Kamran AU, Liu Y, Li FE, et al. Transcatheter arterial chemoembolization with gelatin sponge microparticles treated for BCLC stage B hepatocellular carcinoma: a single center retrospective study. Medicine. 2015;94(52):e2154. doi:10.1097/MD.0000000000002154
   PubMed Web of Science ®Google Scholar
• Zhao GS, Liu S, Liu Y, et al. Clinical application of gelatin sponge microparticles combined with pirarubicin for hepatic transcatheter arterial chemoembolization in breast cancer liver metastasis treatment: results of a single-center long-term study. World J Surg Oncol. 2021;19(1):249. doi:10.1186/s12957-021-02332-0
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines); Hepatobiliary Cancers. Version 5.2022. Fort Washington: National Comprehensive Cancer Network; 2023.
   Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238–iv255. doi:10.1093/annonc/mdy308
   PubMed Web of Science ®Google Scholar
• Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–820. doi:10.1016/S1470-2045(20)30156-X
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Kurosaki M, Marusawa H, et al. The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the Phase 3 trial (REFLECT trial) in real-world practice in Japan: a nationwide multicenter study in Japan. J Clin Oncol. 2019;37(15_suppl):e15629. doi:10.1200/JCO.2019.37.15_suppl.e15629
   Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Galle PR, Tovoli F, Foerster F, et al. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J Hepatol. 2017;67(1):173–183. doi:10.1016/j.jhep.2017.03.007
   PubMed Web of Science ®Google Scholar
• Zhu H, Shan Y, Ge K, et al. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol Dordr. 2020;43(6):1203–1214. doi:10.1007/s13402-020-00552-2
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6(18):18. doi:10.1186/2045-824X-6-18
   PubMedGoogle Scholar
• Deng H, Kan A, Lyu N, et al. Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma. Liver Cancer. 2020;9(3):338–357. doi:10.1159/000505695
   PubMed Web of Science ®Google Scholar
• Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010;10(7):505–514. doi:10.1038/nrc2868
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Katyal S, Oliver JH, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216(3):698–703. doi:10.1148/radiology.216.3.r00se24698
   PubMed Web of Science ®Google Scholar
• Uka K. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastrol. 2007;13(3):414–420. doi:10.3748/wjg.v13.i3.414
   PubMed Web of Science ®Google Scholar
• Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-pacific primary liver cancer expert consensus statements. Liver Cancer. 2020;9(3):245–260. doi:10.1159/000507370
   PubMed Web of Science ®Google Scholar